Hormone replacement therapy use and the risk of stroke

Maturitas

Volumn 61, Issue 4, 2008, Pages 305-309

  Renoux, Christel ^a   Dell'Aniello, Sophie ^a   Garbe, Edeltraut ^b   Suissa, Samy ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF BREMEN   (Germany)

Author keywords

Cerebrovascular event; Estrogen; Hormone therapy; Menopause tibolone; Stroke

Indexed keywords

ESTROGEN; GESTAGEN; TIBOLONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ESTROGEN ACTIVITY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; RISK FACTOR; SENSITIVITY ANALYSIS; STROKE;

AGED; CASE-CONTROL STUDIES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; NORPREGNENES; PROGESTINS; RISK FACTORS; STROKE;

EID: 57849125826     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2008.09.020     Document Type: Article

References (32)

1. Grady D., Rubin S.M., Petitti D.B., et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Int Med 117 December (12) (1992) 1016-1037
2. Barrett-Connor E., and Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 19 (1998) 55-72
3. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 July (3) (2002) 321-333
4. Reed M.J., and Kloosterboer H.J. Tibolone: a selective tissue estrogenic activity regulator (STEAR). Maturitas 48 August (Suppl. 1) (2004) S4-S6
5. Cummings S.R., Ettinger B., Delmas P.D., et al. The effects of tibolone in older postmenopausal women. N Engl J Med 359 August (7) (2008) 697-708
6. Garcia Rodriguez L.A., and Perez G.S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 45 5 (1998 May) 419-425
7. Jick S.S., Kaye J.A., Vasilakis-Scaramozza C., et al. Validity of the general practice research database. Pharmacotherapy 23 May (5) (2003) 686-689
8. Jick H., Jick S.S., and Derby L.E. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 302 March (6779) (1991) 766-768
9. Andersohn F., Schade R., Suissa S., and Garbe E. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study. Stroke 37 July (7) (2006) 1725-1730
10. Archer D.F., Hendrix S., Gallagher J.C., et al. Endometrial effects of tibolone. J Clin Endocrinol Metab 92 March (3) (2007) 911-918
11. Beral V., Green J., Reeves G., and Bull D. Fatal stroke in postmenopausal users of tibolone and hormonal therapy. BMJ 24 October (2006) Ref Type: Generic
12. Shapiro S. Adverse neoplastic and cardiovascular outcomes of HRT: the validity of the evidence. Endocrine 24 August (3) (2004) 203-210
13. Viscoli C.M., Brass L.M., Kernan W.N., Sarrel P.M., Suissa S., and Horwitz R.I. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345 October (17) (2001) 1243-1249
14. Wassertheil-Smoller S., Hendrix S.L., Limacher M., et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 289 May (20) (2003) 2673-2684
15. Hendrix S.L., Wassertheil-Smoller S., Johnson K.C., et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 113 May (20) (2006) 2425-2434
16. Vogelvang T.E., van der Mooren M.J., and Mijatovic V. Hormone replacement therapy, selective estrogen receptor modulators, and tissue-specific compounds: cardiovascular effects and clinical implications. Treat Endocrinol 3 2 (2004) 105-115
17. Kloosterboer H.J., and Ederveen A.G. Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (+/-progestogen) treatments. J Steroid Biochem Mol Biol 83 December (1-5) (2002) 157-165
18. Nelson H.D. Menopause. Lancet 371 March (9614) (2008) 760-770
19. Kloosterboer H.J. Tissue-selectivity: the mechanism of action of tibolone. Maturitas 48 August (Suppl. 1) (2004) S30-S40
20. Winkler U.H., Altkemper R., Kwee B., Helmond F.A., and Coelingh Bennink H.J. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study. Fertil Steril 74 July (1) (2000) 10-19
21. Bjarnason N.H., Bjarnason K., Haarbo J., Bennink H.J., and Christiansen C. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab 82 June (6) (1997) 1752-1756
22. Simoncini T., Mannella P., Fornari L., et al. Tibolone activates nitric oxide synthesis in human endothelial cells. J Clin Endocrinol Metab 89 September (9) (2004) 4594-4600
23. Cicinelli E., Ignarro L.J., Galantino P., Pinto V., Barba B., and Schonauer S. Effects of tibolone on plasma levels of nitric oxide in postmenopausal women. Fertil Steril 78 September (3) (2002) 464-468
24. Haenggi W., Linder H.R., Birkhaeuser M.H., and Schneider H. Microscopic findings of the nail-fold capillaries-dependence on menopausal status and hormone replacement therapy. Maturitas 22 June (1) (1995) 37-46
25. Dansuk R., Unal O., Karageyim Y., Esim E., and Turan C. Evaluation of the effect of tibolone and transdermal estradiol on triglyceride level in hypertriglyceridemic and normotriglyceridemic postmenopausal women. Gynecol Endocrinol 18 May (5) (2004) 233-239
26. Milner M.H., Sinnott M.M., Cooke T.M., Kelly A., McGill T., and Harrison R.F. A 2-year study of lipid and lipoprotein changes in postmenopausal women with tibolone and estrogen-progestin. Obstet Gynecol 87 April (4) (1996) 593-599
27. Clarkson T.B., Anthony M.S., Mikkola T.S., and St Clair R.W. Comparison of tibolone and conjugated equine estrogens effects on carotid artery atherosclerosis of postmenopausal monkeys. Stroke 33 November (11) (2002) 2700-2703
28. Zandberg P., Peters J.L., Demacker P.N., Smit M.J., de Reeder E.G., and Meuleman D.G. Tibolone prevents atherosclerotic lesion formation in cholesterol-fed, ovariectomized rabbits. Arterioscler Thromb Vasc Biol 18 December (12) (1998) 1844-1854
29. Bots M.L., Evans G.W., Riley W., et al. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tibolone (OPAL) study. Eur Heart J 27 March (6) (2006) 746-755
30. Castelo-Branco C., Garcia-Fantini M., and Haya J. Vascular reactivity and atheromatous plaques in post-menopausal women on tibolone treatment. Open prospective study with Doppler ultrasonography in internal carotid artery. Maturitas 50 April (4) (2005) 259-265
31. Erenus M., Ilhan A.H., and Elter K. Effect of tibolone treatment on intima-media thickness and the resistive indices of the carotid arteries. Fertil Steril 79 February (2) (2003) 268-273
32. Hall G.C., Brown M.M., Mo J., and MacRae K.D. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 62 February (4) (2004) 563-568